PRIME MEDICINE INC (PRME) Forecast, Price Target & Analyst Ratings
NASDAQ:PRME • US74168J1016
4.12 USD
-0.11 (-2.6%)
At close: Mar 4, 2026
4.2 USD
+0.08 (+1.94%)
After Hours: 3/4/2026, 8:00:01 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PRIME MEDICINE INC (PRME).
Forecast Snapshot
Consensus Price Target
$6.59
+ 60.04% Upside
Next Earnings Forecast
Release DateMay 6, 2026
PeriodQ4 / 2025
EPS Estimate-$0.26
Revenue Estimate2.387M
ChartMill Buy Consensus
80.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$6.59
Upside
+ 60.04%
From current price of $4.12 to mean target of $6.59, Based on 17 analyst forecasts
Low
$4.29
Median
$6.12
High
$9.45
Price Target Revisions
1 Month
0.00%
3 Months
-3.64%
Price Target Summary
17 analysts have analysed PRME and the average price target is 6.59 USD. This implies a price increase of 60.04% is expected in the next year compared to the current price of 4.12.
The average price target has been revised downward by 3.64% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
PRME was analyzed by 17 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about PRME.
In the previous month the buy percentage consensus was at a similar level.
PRME was analyzed by 17 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-23 | LifeSci Capital | Initiate | Outperform |
| 2025-11-11 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-11-10 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-27 | Citigroup | Downgrade | Buy -> Neutral |
| 2025-05-20 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-05-20 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2025-05-20 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-05-19 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-20 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-04 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-03-03 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-10 | JMP Securities | Initiate | Market Outperform |
| 2024-12-03 | Guggenheim | Reiterate | Buy -> Buy |
| 2024-11-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-11-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-20 | HC Wainwright & Co. | Initiate | Buy |
| 2024-05-16 | Citigroup | Upgrade | Neutral -> Buy |
| 2024-05-13 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-04-23 | Wedbush | Reiterate | Outperform -> Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 6, 2026
PeriodQ4 / 2025
EPS Estimate-$0.26
Revenue Estimate2.387M
Revenue Q2Q9.34%
EPS Q2Q17.27%
Number of Analysts14
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
18.58%
EPS (1 Month)
0.00%
EPS (3 Months)
-1.35%
Next Earnings Summary
PRME is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -0.26 USD and the consensus revenue estimate is 2.39M USD.
The next earnings revenue estimate has been revised upward by 18.58% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.983M | 5.835M 95.61% | 5.336M -8.55% | 22.21M 316.23% | 2.356M -89.39% | 7.009M 197.50% | 20.754M 196.11% | 111.87M 439.03% | 520.47M 365.25% | 1.009B 93.86% | |||
| EBITDA YoY % growth | -114.32M -36.26% | -200.139M -75.07% | -196.339M 1.90% | -196.966M -0.32% | -163.331M 17.08% | -176.637M -8.15% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -116.54M -37.97% | -204.792M -75.73% | -202.467M 1.14% | -205.239M -1.37% | -175.421M 14.53% | -188.171M -7.27% | -211.785M -12.55% | -216M -1.99% | -201.181M 6.86% | -138.585M 31.11% | 199.31M 243.82% | 524.59M 163.20% | |
| Operating Margin | N/A | N/A | -6,787.36% | -3,517.37% | -3,287.50% | -847.23% | -8,989.19% | -3,081.76% | -969.36% | -123.88% | 38.29% | 51.99% | |
| EPS YoY % growth | N/A | -2.18 26.93% | -1.65 24.31% | -1.34 18.73% | -0.96 28.72% | -0.89 6.48% | -0.87 3.02% | -0.78 10.00% | -0.70 10.78% | -0.34 51.65% | 0.77 327.27% | 2.24 192.67% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.26 17.27% | -0.25 38.67% | -0.24 40.82% | -0.25 22.86% | -0.27 -4.08% | -0.29 -19.33% | -0.31 -28.64% | -0.32 -27.69% | -0.33 -22.29% | -0.35 -20.21% | -0.38 -21.57% | -0.38 -21.68% |
| Revenue Q2Q % growth | 2.387M 9.34% | 510K -64.92% | 7.293M 554.08% | 7.293M 495.35% | -100.00% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | -44.536M -16.91% | -35.433M 30.10% | -38.302M 23.11% | -39.148M 19.33% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -47.709M -7.89% | -40.925M 21.89% | -42.261M 20.83% | -43.903M 18.66% | -49.062M -2.84% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
13.40%
EPS Next 5 Year
8.84%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
186.17%
Revenue Next 5 Year
49.21%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
5.34%
EBIT Next 5 Year
N/A
PRIME MEDICINE INC / PRME Forecast FAQ
What is the price target for PRME stock?
17 analysts have analysed PRME and the average price target is 6.59 USD. This implies a price increase of 60.04% is expected in the next year compared to the current price of 4.12.
When does PRIME MEDICINE INC (PRME) report earnings?
PRIME MEDICINE INC (PRME) will report earnings on 2026-05-06.
What are the consensus estimates for PRME stock next earnings?
The consensus EPS estimate for the next earnings of PRIME MEDICINE INC (PRME) is -0.26 USD and the consensus revenue estimate is 2.39M USD.
How do analysts rate PRIME MEDICINE INC (PRME)?
The consensus rating for PRIME MEDICINE INC (PRME) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.